Generative AI for Drug Discovery: Making Medicine Faster

Using generative AI for drug discovery can help make developing pharmaceutical medicine faster, easier, and cheaper, getting people the medicine they need.

As the current hot-button topic in technology, generative AI is already being explored for industries ranging from oil and gas to banking and education. In the field of healthcare, one of the most exciting applications for the technology lies with drug discovery, leading to drug development that is faster and less expensive.

How Generative AI Can Be Used in Drug Discovery
With an estimated ten to the sixtieth power number of possible drug-like molecules in existence, it would be impossible to discover, create, and test all of them. Even starting from a practical base, it can take decades and cost billions to go from concept to clinical trials to public release.

Generative AI can cut through these time and costs, helping create new drugs faster and more affordably. The primary applications for generative AI in drug discovery include:

Molecule Generation
Generative AI can simulate entire molecular structures and their interactions with a patient’s body. This can be used to simulate molecules with desirable properties that remain safe for use in patients. AI models can combine multiple techniques for molecule design, significantly accelerating drug development.

Antibody Design
Generative AI can be trained on protein sequences and used to create specific antibodies that target specific pathogens. These protein language models can improve the quality and speed of antibody design, and even develop antibodies that are “zero-shot,” meaning they are created without any training data of antibodies known to bind to those specific targets.

Drug Repurposing
By reviewing existing scientific knowledge and documentation using AI, pharmaceutical companies can identify new uses for drugs already approved for public use. This helps companies avoid the typical development costs associated with discovery. For example, the drug semaglutide was originally created to help people manage type 2 diabetes, but was later adopted for weight loss as Ozempic. AI algorithms can model clinical trials that simulate a wide range of individuals across genders, ethnicities, comorbidities, and other factors that may influence a drug’s effects.

De Novo Drug Design
AI models are currently used to generate and predict novel molecular structures that interact with biological targets. Essentially, it attempts to create drug molecules from scratch rather than modify existing compounds. This approach to chemistry has been applied to atom-based, fragment-based, and reaction-based approaches for creating new structures, giving researchers multiple angles to approach a problem.

Precision Drug Development
Precision drugs are highly desirable in healthcare, as they can help physicians treat a patient’s condition more accurately than a generic prescription. However, creating custom medication for every individual patient is obviously impractical under the current drug development paradigm. Using generative AI to analyze multiple datasets, such as a patient’s health information, genetics, biobank studies, and more, can help design drugs that are tailored to the patient’s specific needs.

Benefits of Generative AI for Drug Discovery
Using generative AI for drug discovery isn’t simply a matter of using the newest, shiniest tool. It’s the key to developing better drugs and making them faster and cheaper.

Lower Costs
One of the most common complaints about healthcare in general and pharmaceuticals specifically is the cost of medication. Much of that cost stems from the development and testing of successive iterations of the same drug, aimed at amplifying its positive effects while mitigating its adverse effects. Generative AI’s ability to sift through enormous amounts of data to find the right combination of molecules to produce a viable drug cuts down on the dead ends and wasted effort, lowering the cost of creating a new drug.

Faster Time to Market
With an average time of twelve to fifteen years to obtain a novel drug, too many patients are forced to wait for potentially life-saving treatment. Additionally, new drugs and treatments are needed to counter the rising threat of antibiotic-resistant bacteria, an issue that contributes to nearly 5 million deaths every year. This isn’t merely a question of a pharmaceutical company’s profit margins, but a matter of life and death for patients worldwide. Getting better drugs to the market faster, thanks to generative AI, can save lives.

Greater Treatment Accuracy
If you’ve ever seen an advertisement for a new pharmaceutical drug, you’ve probably seen the laundry list of side effects that they leave for the end of the ad. AI-designed drugs promise to be more accurate and refined, meaning they will have fewer adverse side effects as they work. Precision drugs tailored to an individual’s body can achieve greater effectiveness, leading to faster treatment and easier recovery.

Challenges for AI-Based Drug Discovery
Like any innovation, artificial intelligence presents hurdles to overcome. The most significant of these challenges comes with supporting and using these AI models effectively.

Avoiding AI Hallucinations
One of the major limitations of AI is its tendency to “hallucinate,” producing incorrect results that are impossible to achieve. For example, it might suggest chemical compounds that are physically impossible to synthesize under real-world conditions. The solution to this issue is to use AI models specifically trained on known, valid molecules and chemical reactions, such as Stanford Medicine’s SyntheMol AI. This helps ensure that the AI only suggests drugs that can be created.

Hardware Support
Modern AI models are heavily dependent on parallel processing, which enables them to analyze large volumes of data simultaneously. However, parallel processing requires specialized computers equipped with appropriate hardware, such as GPUs designed for this task. Healthcare and pharmaceutical groups interested in using generative AI need to use specialized tools like medical AI box PCs to support it.

Cost of Implementation
As with any new tool, there is a price tag attached to AI. Both the hardware needed to run AI models and the licenses to use them can cost healthcare groups and pharmaceutical companies a pretty penny. One way to ameliorate this cost is to work with an original equipment manufacturer (OEM) for your hardware needs. These companies specialize in customizing products to fit the exact needs of the end-user, which helps you get the performance and features you need without overpaying for things that you don’t.

Embrace AI Drug Discovery with Cybernet Manufacturing
While there are challenges associated with its adoption, using generative AI for drug discovery could revolutionize the pharmaceutical industry, leading to better outcomes for patients around the world.

If your healthcare group or pharmaceutical company needs computer hardware capable of supporting AI models, contact the team at Cybernet Manufacturing today. We offer AI computers equipped with the latest in NVIDIA GPUs that can handle a range of parallel processing tasks, and we can customize our products to better fit your specific requirements.